ImmunityBio (IBRX) Income from Non-Controlling Interests (2020 - 2026)
ImmunityBio (IBRX) reported Income from Non-Controlling Interests of -$15000.0 for Q1 2026, up 25.0% year-over-year from -$12000.0 in Q1 2025, and down 7.14% quarter-over-quarter from -$14000.0 in Q4 2025.
ImmunityBio (IBRX) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 7 years of Income from Non-Controlling Interests data on file, last reported at -$15000.0 in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at -$15000.0, up 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$69000.0 (up 13.75% YoY), and the FY2025 annual result was -$74000.0, up 8.64% from the prior year.
- Income from Non-Controlling Interests fell to -$15000.0 in Q1 2026 per IBRX's latest filing, from -$14000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$14000.0 in Q4 2025 and troughed at -$334000.0 in Q2 2023.
- A 5-year average of -$92882.4 and a median of -$22000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests tumbled 39.53% in 2023, then jumped 94.01% in 2024.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$111000.0 in 2022, then jumped by 80.18% to -$22000.0 in 2023, then advanced by 22.73% to -$17000.0 in 2024, then grew by 17.65% to -$14000.0 in 2025, then fell by 7.14% to -$15000.0 in 2026.
- Business Quant data shows IBRX's Income from Non-Controlling Interests at -$15000.0 in Q1 2026, -$14000.0 in Q4 2025, and -$21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -20,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -60,000.00 |
| Jun 30, 2023 | -334,000.00 |
| Mar 31, 2023 | -240,000.00 |
| Dec 31, 2022 | -111,000.00 |
| Sep 30, 2022 | -223,000.00 |
| Jun 30, 2022 | -247,000.00 |
| Mar 31, 2022 | -172,000.00 |
| Dec 31, 2021 | -294,000.00 |
| Sep 30, 2021 | -800,000.00 |
| Jun 30, 2021 | -1.10 Mn |